Premium
Evolving Impact of COVID‐19 on Transplant Center Practices and Policies in the United States
Author(s) -
Boyarsky Brian J.,
Ruck Jessica M.,
Chiang Teresa PoYu,
Werbel William A.,
Strauss Alexandra T.,
Getsin Samantha N.,
Jackson Kyle R.,
Kernodle Amber B.,
Van Pilsum Rasmussen Sarah E.,
Baker Talia B.,
Al Ammary Fawaz,
Durand Christine M.,
Avery Robin K.,
Massie Allan B.,
Segev Dorry L.,
GaronzikWang Jacqueline M.
Publication year - 2020
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.14086
Subject(s) - medicine , covid-19 , transplantation , organ procurement , kidney transplantation , incidence (geometry) , single center , intensive care medicine , surgery , virology , physics , disease , outbreak , infectious disease (medical specialty) , optics
In our first survey of transplant centers in March 2020, >75% of kidney and liver programs were either suspended or operating under restrictions. To safely resume transplantation, we must understand the evolving impact of COVID‐19 on transplant recipients and center‐level practices. We therefore conducted a six‐week follow‐up survey May 7‐15, 2020, and linked responses to the COVID‐19 incidence map, with a response rate of 84%. Suspension of live donor transplantation decreased from 72% in March to 30% in May for kidneys and from 68% to 52% for livers. Restrictions/suspension of deceased donor transplantation decreased from 84% to 58% for kidneys and from 73% to 42% for livers. Resuming transplantation at normal capacity was envisioned by 83% of programs by August 2020. Exclusively using local recovery teams for deceased donor procurement was reported by 28%. Respondents reported caring for a total of 1166 COVID‐19–positive transplant recipients; 25% were critically ill. Telemedicine challenges were reported by 81%. There was a lack of consensus regarding management of potential living donors or candidates with SARS‐CoV‐2. Our findings demonstrate persistent heterogeneity in center‐level response to COVID‐19 even as transplant activity resumes, making ongoing national data collection and real‐time analysis critical to inform best practices.